Navigation Links
PM Versus MIM: TM&S President to Explain Niche Metal Fabrication Methods During IHS GlobalSpec Event
Date:9/24/2013

Minneapolis, Minnesota (PRWEB) September 24, 2013

Derek Rasmussen, President of TM&S, LLC, will present “Powder Metal Part Design Fundamentals,” a free Webinar taking place on October 23, 2013, at 12:30 P.M. EST, during IHS GlobalSpec’s Aerospace Technology online event.

The informational session will help engineering, sales, and other professionals involved in component design for manufacture (DFM) understand the characteristics and best uses for Press and Sinter (conventional powder metal, or PM) and Metal Injection Molding (MIM), respectively. Both are classified as powder metal technologies and are used in the medical device, computer, communications, automotive, firearms, defense, aerospace, and consumer electronics industries. But there are vast differences between them in terms of manufacturing processes and capabilities.

With 20 years’ experience in component design, mold design, part processing, and troubleshooting high-volume manufacturing processes to increase yields, Mr. Rasmussen is uniquely qualified to give attendees a fundamental comparison of PM and MIM manufacturing technologies. His Webinar will help participants improve their cost analysis and sourcing decisions, as well as enhance communication with suppliers.

TM&S, LLC, is a trusted resource for custom component designers and manufacturers. It exclusively represents four companies specializing in niche powder metal technologies: ecoMIM of Retsag, Hungary (Metal Injection Molding); element22 of Kiel, Germany (Titanium MIM); FMS Corporation of Minneapolis, Minnesota (Press and Sinter and Micro MIM); and Liquidmetal Technologies of Rancho Santa Margarita, California. Their complementary capabilities allow TM&S to provide the best solution for any component suited to powder metal technology, whether round parts, complex geometric profiles, micro parts with high tolerances, or low-cost Titanium parts.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11150788.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
2. TM&S Opens Office Dedicated to Powder Metal, Metal Injection Molding and Liquid Metal
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Elsevier / MEDai Appoints Tom Zajac as New President
5. GenVec President and Chief Executive Officer Announces Retirement
6. Michael A. Marletta Takes Office as New President of Scripps Research Institute
7. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
8. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Zyga Technology, Inc. Announces the Appointment of Jim Bullock as President and CEO
11. Cepheid Welcomes Senior Vice President of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):